Ribaxamase is a recombinant enzyme commercialized by Theriva Biologics, with a leading Phase II program in Infectious Diarrhea. According to Globaldata, it is involved in 7 clinical trials, of which 6 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Ribaxamase’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ribaxamase is expected to reach an annual total of $75 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SYN-004 is under development for the protection of the gut microbiome from beta-lactam antibiotics used for the prevention of C. difficile infections, acute graft versus host disease (aGVHD) in allogeneic hematopoietic cell transplant and antibiotic-associated diarrhea (AAD). The drug candidate is administered orally. SYN-004 has structural and functional similarities to naturally occurring beta-lactamases in the gastrointestinal (GI) microflora. It has CDI and VRE colonization in allogeneic HCT recipients.
Theriva Biologics Overview
Theriva Biologics (Theriva), formerly Synthetic Biologics Inc, is a Biotechnology company. It develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is intended to treat rritable bowel syndrome with constipation. Theriva’s SYN-004 is an oral prophylactic therapy for prevention of clostridium difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance. It develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria. The company undertakes various research activities to develop therapeutics. It collaborates with various academic and pharmaceutical companies to develop its product candidates. Theriva is headquartered in Rockville, Maryland, the US.
The operating loss of the company was US$14.3 million in FY2021, compared to an operating loss of US$10.2 million in FY2020. The net loss of the company was US$14.3 million in FY2021, compared to a net loss of US$10 million in FY2020.
For a complete picture of Ribaxamase’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.